Twenty years of polymers: A personal perspective on alpha-1 antitrypsin deficiency

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 10, Issue S1, 2013, Pages 17-25

  Lomas, David A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cirrhosis; Emphysema; Pathogenesis; Serpin; Serpinopathies; Treatment

Indexed keywords

ALPHA 1 ANTITRYPSIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2C1; POLYMER; UNCLASSIFIED DRUG;

ALPHA 1 ANTITRYPSIN DEFICIENCY; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; LIVER DISEASE; LUNG EMPHYSEMA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN POLYMERIZATION; REVIEW; SURVIVAL; SYSTEMIC DISEASE;

ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; ANTIBODIES, MONOCLONAL; HEPATOCYTES; HUMANS; POLYMERS; PULMONARY EMPHYSEMA;

EID: 84875673488     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2013.764401     Document Type: Review

References (93)

1. Gooptu B, Lomas DA. Polymers and inflammation: disease mechanisms of the serpinopathies. J Exp Med 2008; 205:1529- 1534.
2. Gooptu B, Lomas DA. Conformational pathology of the serpins - themes, variations and therapeutic strategies. Annu Rev Biochem 2009; 78:147-176.
3. Ekeowa UI, Gooptu B, Belorgey D, Hagglof P, Karlsson-Li S, Miranda E, et al. alpha1-Antitrypsin deficiency, chronic obstructive pulmonary disease and the serpinopathies. Clin Sci (Lond) 2009; 116(12):837-850.
4. Irving JA, Ekeowa UI, Belorgey D, Haq I, Gooptu B, Miranda E, et al. The serpinopathies: studying serpin polymerization in vivo. Meth Enzymol 2011; 501:421-466.
5. Dickens JA, Lomas DA. Why has it been so difficult to prove the efficacy of alpha-1-antitrypsin replacement therapy? Insights from the study of disease pathogenesis. Drug Des Devel Ther 2011; 5:391-405.
6. Laurell C-B, Eriksson S. The electrophoretic a1-globulin pattern of serum in α1-antitrypsin deficiency. Scand J Clin Lab Invest 1963; 15:132-140.
7. Sharp HL, Bridges RA, Krivit W, Freier EF. Cirrhosis associated with alpha-1-antitrypsin deficiency: A previously unrecognised inherited disorder. J Lab Clin Med 1969; 73(6):934-939.
8. Loebermann H, Tokuoka R, Deisenhofer J, Huber R. Human α1-proteinase inhibitor. Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. J Mol Biol 1984; 177:531-557.
9. Elliott PR, Lomas DA, Carrell RW, Abrahams J-P. Inhibitory conformation of the reactive loop of α1-antitrypsin. Nat Struct Biol 1996; 3(8):676-681.
10. Elliott PR, Abrahams J-P, Lomas DA. Wildtype α1-antitrypsin is in the canonical inhibitory conformation. J Mol Biol 1998; 275(3):419-425.
11. Elliott PR, Pei XY, Dafforn TR, Lomas DA. Topography of a 2.0A structure of α1-antitrypsin reveals targets for rational drug design to prevent conformational disease. Protein Sci 2000; 9:1274-1281.
12. Ryu S-E, Choi H-J, Kwon K-S, Lee KN, Yu M-H. The native strains in the hydrophobic core and flexible reactive loop of a serine protease inhibitor: crystal structure of an uncleaved α1-antitrypsin at 2.7A. Structure 1996; 4:1181-1192.
13. Huntington JA, Read RJ, Carrell RW. Structure of a serpinprotease complex shows inhibition by deformation. Nature 2000; 407:923-926.
14. Lomas DA, Evans DL, Finch JT, Carrell RW. The mechanism of Z α1-antitrypsin accumulation in the liver. Nature 1992; 357:605-607.
15. Lomas DA, Evans DL, Stone SR, Chang W-SW, Carrell RW. Effect of the Z mutation on the physical and inhibitory properties of α1-antitrypsin. Biochemistry 1993; 32:500-508.
16. Skinner R, Chang W-SW, Jin L, Pei X, Huntington JA, Abrahams J-P, et al. Implications for function and therapy of a 2.9A structure of binary-complexed antithrombin. J Mol Biol 1998; 283(1):9-14.
17. Lomas DA, Finch JT, Seyama K, Nukiwa T, Carrell RW. α1-antitrypsin Siiyama (Ser53→Phe); further evidence for intracellular loop-sheet polymerisation. J Biol Chem 1993; 268:15333-15335.
18. Lomas DA, Elliott PR, Sidhar SK, Foreman RC, Finch JT, Cox DW, et al. Alpha1-antitrypsin Mmalton (52Phe deleted) forms loop-sheet polymers in vivo: evidence for the C sheet mechanism of polymerisation. J Biol Chem 1995; 270(28):16864-16870.
19. Miranda E, Perez J, Ekeowa UI, Hadzic N, Kalsheker N, Gooptu B, et al. A novel monoclonal antibody to characterise pathogenic polymers in liver disease associated with α1-antitrypsin deficiency. Hepatology 2010; 52:1078-1088.
20. Elliott PR, Stein PE, Bilton D, Carrell RW, Lomas DA. Structural explanation for the dysfunction of S α1-antitrypsin. Nat Struct Biol 1996; 3(10):910-911.
21. Mahadeva R, Chang W-SW, Dafforn TR, Oakley DJ, Foreman RC, Calvin J, et al. Heteropolymerisation of S, I and Z α1-antitrypsin and liver cirrhosis. J Clin Invest 1999; 103:999- 1006.
22. Dafforn TR, Mahadeva R, Elliott PR, Sivasothy P, Lomas DA. A kinetic mechanism for the polymerisation of α1-antitrypsin. J Biol Chem 1999; 274:9548-9555.
23. Gooptu B, Hazes B, Chang W-SW, Dafforn TR, Carrell RW, Read R, et al. Inactive conformation of the serpin α1-antichymotrypsin indicates two stage insertion of the reactive loop; implications for inhibitory function and conformational disease. Proc Natl Acad Sci USA 2000; 97(1):67-72.
24. Yu M-H, Lee KN, Kim J. The Z type variation of human α1-antitrypsin causes a protein folding defect. Nat Struct Biol 1995; 2(5):363-367.
25. Kang HA, Lee KN, Yu M-H. Folding and stability of the Z and Siiyama genetic variants of human α1-antitrypsin. J Biol Chem 1997; 272(1):510-516.
26. Wu Y, Swulius MT, Moremen KW, Sifers RN. Elucidation of the molecular logic by which misfolded α1-antitrypsin is preferentially selected for degradation. Proc Natl Acad Sci USA 2003; 100(14):8229-8234.
27. Le A, Ferrell GA, Dishon DS, Quyen-Quyen AL, Sifers RN. Soluble aggregates of the human PiZ α1-antitrypsin variant are degraded within the endoplasmic reticulum by a mechanism sensitive to inhibitors of protein synthesis. J Biol Chem 1992; 267(2):1072-1080.
28. Qu D, Teckman JH, Omura S, Perlmutter DH. Degradation of a mutant secretory protein, α1-antitrypsin Z, in the endoplasmic reticulum requires proteosome activity. J Biol Chem 1996; 271(37):22791-22795.
29. Kroger H, Miranda E, MacLeod I, Perez J, Crowther DC, Marciniak SJ, et al. Endoplasmic reticulum-associated degradation (ERAD) and autophagy cooperate to degrade polymerogenic mutant serpins. J Biol Chem 2009; 284(34):22793-22802.
30. James EL, Bottomley SP. The mechanism of α1-antitrypsin polymerization probed by fluorescence spectroscopy. Arch Biochem Biophys 1998; 356:296-300.
31. Sivasothy P, Dafforn TR, Gettins PGW, Lomas DA. Pathogenic α1-antitrypsin polymers are formed by reactive loop-®-sheet A linkage. J Biol Chem. 2000; 275(43):33663-33668.
32. Purkayastha P, Klemke JW, Lavender S, Oyola R, Cooperman BS, Gai F. α1-antitrypsin polymerisation: A fluorescence correlation spectroscopic study. Biochemistry 2005; 44(7):2642-2649.
33. Cabrita LD, Dai W, Bottomley SP. Different conformational changes within the F-helix occur during serpin folding, polymerization and proteinase inhibition. Biochemistry 2004; 43:9834-9839.
34. Baek JH, Im H, Kang UB, Seong KM, Lee C, Kim J, et al. Probing the local conformational change of α1-antitrypsin. Protein Sci 2007; 16(9):1842-1850.
35. Gooptu B, Miranda E, Nobeli I, Mallya M, Purkiss A, Leigh Brown SC, et al. Crystallographic and cellular characterisation of two mechanisms stabilising the native fold of alpha-1- antitrypsin: implications for disease and drug design. J Mol Biol 2009; 387(4):857-868.
36. Nyon MP, Segu L, Cabrita LD, Levy GR, Kirkpatrick J, Roussel BD, et al. Structural dynamics associated with intermediate formation in an archetypal conformational disease. Structure 2012; 20(3):504-512.
37. Schulze AJ, Baumann U, Knof S, Jaeger E, Huber R, Laurell C-B. Structural transition of α1-antitrypsin by a peptide sequentially similar to ®-strand s4A. Eur J Biochem 1990; 194:51-56.
38. Devlin GL, Chow MKM, Howlett GJ, Bottomley SP. Acid denaturation of α1-antitrypsin: characterization of a novel mechanism of serpin polymerization. J Mol Biol 2002; 324:859-870.
39. Carrell RW, Stein PE, Fermi G, Wardell MR. Biological implications of a 3A structure of dimeric antithrombin. Structure 1994; 2(4):257-270.
40. Zhang Q, Law RH, Bottomley SP, Whisstock JC, Buckle AM. A structural basis for loop C-sheet polymerization in serpins. J Mol Biol 2008; 376(5):1348-1359.
41. Sharp AM, Stein PE, Pannu NS, Carrell RW, Berkenpas MB, Ginsburg D, et al. The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion. Structure 1999; 7:111-118.
42. McGowan S, Buckle AM, Irving JA, Ong PC, Bashtannyk- Puhalovich TA, Kan WT, et al. X-ray crystal structure of MENT: evidence for functional loop-sheet polymers in chromatin condensation. EMBO J 2006; 25(13):3144-3155.
43. Yamasaki M, Li W, Johnson DJ, Huntington JA. Crystal structure of a stable dimer reveals the molecular basis of serpin polymerization. Nature 2008; 455:1255-1258.
44. Yamasaki M, Sendall TJ, Pearce MC, Whisstock JC, Huntington JA. Molecular basis of α1-antitrypsin deficiency revealed by the structure of a domain-swapped trimer. EMBO Rep 2011; 12(10):1011-1017.
45. Krishnan B, Gierasch LM. Dynamic local unfolding in the serpin α1-antitrypsin provides a mechanism for loop insertion and polymerization. Nat Struct Mol Biol 2011; 18(2):222-226.
46. Ekeowa UI, Freekeb J, Miranda E, Gooptu B, Bush MF, Perez J, et al. Defining the mechanism of polymerization in the serpinopathies. Proc Natl Acad Sci USA 2010; 107(40):17146- 17151.
47. Belorgey D, Irving JA, Ekeowa UI, Freeke J, Roussel BD, Miranda E, et al. Characterisation of serpin polymers in vitro and in vivo. Methods 2011; 53(3):255-266.
48. Bamforth FJ, Kalsheker NA. Alpha1 antitrypsin deficiency due to Pi null: clinical presentation and evidence for molecular heterogeneity. J Med Genet 1988; 25:83-87.
49. Elliott PR, Bilton D, Lomas DA. Lung polymers in Z α1-antitrypsin related emphysema. Am J Respir Cell Mol Biol 1998; 18(5):670-674.
50. Mulgrew AT, Taggart CC, Lawless MW, Greene CM, Brantly ML, O'Neill SJ, et al. Z α1-antitrypsin polymerizes in the lung and acts as a neutrophil chemoattractant. Chest 2004; 125:1952-1957.
51. Wardell MR, Lomas DA, Brecht WJ, Mahley RW. Proteasecomplexed and polymerised antithrombin and α1-antitrypsin bind low density lipoprotein receptor-related protein. Protein Sci 1994; 3 Suppl. 1:101-S.
52. Banda MJ, Rice AG, Griffin GL, Senior RM. The inhibitory complex of human α1-proteinase inhibitor and human leukocyte elastase is a neutrophil chemoattractant. J Exp Med 1988; 167:1608-1615.
53. Parmar JS, Mahadeva R, Reed BJ, Farahi N, Cadwallader K, Bilton D, et al. Polymers of α1-antitrypsin are chemotactic for human neutrophils: a new paradigm for the pathogenesis of emphysema. Am J Respir Cell Mol Biol 2002; 26:723-730.
54. Mahadeva R, Atkinson C, Li J, Stewart S, Janciauskiene S, Kelley DG, et al. Polymers of Z α1-antitrypsin co-localise with neutrophils in emphysematous alveoli and are chemotactic in vivo. Am J Pathol 2005; 166(2):377-386.
55. Alam S, Li Z, Janciauskiene S, Mahadeva R. Oxidation of Z alpha-1-antitrypsin by cigarette smoke induces polymerization: a novel mechanism of early-onset emphysema. Am J Respir Cell Mol Biol 2011; 45:261-269.
56. Rashid ST, Corbineau S, Hannan N, Marciniak SJ, Miranda E, Alexander G, et al. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J Clin Invest 2010; 120(9):3127-3136.
57. Esnault VLM, Testa A, Audrain M, Roge C, Hamidou M, Barrier JH, et al. Alpha1-antitrypsin genetic polymorphism in ANCA-positive systemic vasculitis. Kidney Inter 1993; 43(6):1329-1332.
58. Lyons PA, Rayner TF, Trivedi S, Holle JU, Watts RA, Jayne DR, et al. Genetically distinct subsets within ANCA-Associated vasculitis. N Engl J Med 2012; 367:214-223.
59. Morris H, Morgan MD, Wood AM, Smith SW, Ekeowa UI, Herrmann K, et al. ANCA-associated vasculitis is linked to carriage of the Z allele of α1-antitrypsin and its polymers. Ann Rheum Dis 2011; 70(10):1851-1856.
60. Gross B, Grebe M, Wencker M, Stoller JK, Bjursten LM, Janciauskiene S. New findings in PiZZ alpha(1)-antitrypsin deficiency-related panniculitis. Demonstration of skin polymers and high dosing requirements of intravenous augmentation therapy. Dermatology 2009; 218(4):370-375.
61. Blanco I, Lara B, de Serres F. Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema. Orphanet J Rare Dis Orphanet J Rare Dis 2011; 6:14.
62. Lomas DA. The selective advantage of α1-antitrypsin deficiency. Am J Respir Crit Care Med 2006; 173:1072-1077.
63. Malerba M, Ricciardolo F, Radaeli A, Torregiani C, Ceriani L, Mori E, et al. Neutrophilic inflammation and IL-8 levels in induced sputum of alpha-1-antitrypsin PiMZ subjects. Thorax 2006; 61(2):129-133.
64. Aulak KS, Eldering E, Hack CE, Lubbers YPT, Harrison RA, Mast A, et al. A hinge region mutation in C1-inhibitor (Ala436 Thr) results in nonsubstrate-like behavior and in polymerization of the molecule. J Biol Chem 1993; 268(24):18088-18094.
65. Eldering E, Verpy E, Roem D, Meo T, Tosi M. COOH-terminal substitutions in the serpin C1 inhibitor that cause loop overinsertion and subsequent multimerization. J Biol Chem 1995; 270(6):2579-2587.
66. Bruce D, Perry DJ, Borg J-Y, Carrell RW, Wardell MR. Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen VI (187 Asn→Asp). J Clin Invest 1994; 94:226-2274.
67. Picard V, Dautzenberg M-D, Villoutreix BO, Orliaguet G, Alhenc-Gelas M, Aiach M. Antithrombin Phe229Leu: a new homozygous variant leading to spontaneous antithrombin polymerisation in vivo associated with severe childhood thrombosis. Blood 2003; 102(3):919-925.
68. Faber J-P, Poller W, Olek K, Baumann U, Carlson J, Lindmark B, et al. The molecular basis of α1-antichymotrypsin deficiency in a heterozygote with liver and lung disease. J Hepatol 1993; 18:313-321.
69. Poller W, Faber J-P, Weidinger S, Tief K, Scholz S, Fischer M, et al. A leucine-to-proline substitution causes a defective α1-antichymotrypsin allele associated with familial obstructive lung disease. Genomics 1993; 17:740-743.
70. Corral J, Aznar J, Gonzalez-Conejero R, Villa P, Minano A, Vaya A, et al. Homozygous deficiency of heparin cofactor II: relevance of P17 glutamate residue in serpins, relationship with conformational diseases, and role in thrombosis. Circulation 2004; 110(10):1303-1307.
71. Hastings GA, Coleman TA, Haudenschild CC, Stefansson S, Smith EP, Barthlow R, et al. Neuroserpin, a brain-associated inhibitor of tissue plasminogen activator is localized primarily in neurones. J Biol Chem 1997; 272(52):33062-33067.
72. Davis RL, Shrimpton AE, Holohan PD, Bradshaw C, Feiglin D, Sonderegger P, et al. Familial dementia caused by polymerisation of mutant neuroserpin. Nature 1999; 401:376- 379.
73. Davis RL, Daucher JW, Welker DM, Bareza MA, Collins GH. A familial dementia with unusual neuronal inclusions. J Neuropath Exp Neurol 1996; 55:636.
74. Davis RL, Shrimpton AE, Carrell RW, Lomas DA, Gerhard L, Baumann B, et al. Association between conformational mutations in neuroserpin and onset and severity of dementia. Lancet 2002; 359:2242-2247.
75. Coutelier M, Andries S, Ghariani S, Dan B, Duyckaerts C, van Rijckevorsel K, et al. Neuroserpin mutation causes electrical status epilepticus of slow-wave sleep. Neurology 2008; 71(1):64-66.
76. Hagen M, Murrell JR, Delisle MB, Andermann E, Andermann F, Guiot MC, et al. Encephalopathy with neuroserpin inclusion bodies presenting as progressive myoclonus epilepsy and associated with a novel mutation in the proteinase inhibitor 12 Gene. Brain Pathol 2011; 21(5):575-582.
77. Belorgey D, Crowther DC, Mahadeva R, Lomas DA. Mutant neuroserpin (Ser49Pro) that causes the familial dementia FENIB is a poor proteinase inhibitor and readily forms polymers in vitro. J Biol Chem 2002; 277:17367-17373.
78. Miranda E, Romisch K, Lomas DA. Mutants of neuroserpin that cause dementia accumulate as polymers within the endoplasmic reticulum. J Biol Chem 2004; 279(27):28283- 28291.
79. Belorgey D, Sharp LK, Crowther DC, Onda M, Johansson J, Lomas DA. Neuroserpin Portland (Ser52Arg) is trapped as an inactive intermediate that rapidly forms polymers: implications for the epilepsy seen in the dementia FENIB. Eur J Biochem 2004; 271(16):3360-3367.
80. Miranda E, McLeod I, Davies MJ, Perez J, Romisch K, Crowther DC, et al. The intracellular accumulation of polymeric neuroserpin explains the severity of the dementia FENIB. Hum Mol Genet 2008; 17:1527-1539.
81. Takehara S, Onda M, Zhang J, Nishiyama M, Yang X, Mikami B, et al. The 2.1-A crystal structure of native neuroserpin reveals unique structural elements that contribute to conformational instability. J Mol Biol 2009; 388(1):11-20.
82. Belorgey D, Hagglof P, Onda M, Lomas DA. pH dependent stability of neuroserpin is mediated by Histidines 119 and 138; implications for the control of ®-sheet A and polymerisation. Protein Sci 2010; 19(2):220-228.
83. Mahadeva R, Dafforn TR, Carrell RW, Lomas DA. Sixmer peptide selectively anneals to a pathogenic serpin conformation and blocks polymerisation: implications for the prevention of Z α1-antitrypsin related cirrhosis. J Biol Chem 2002; 277(9):6771-6774.
84. Parfrey H, Dafforn TR, Belorgey D, Lomas DA, Mahadeva R. Inhibiting polymerisation: new therapeutic strategies for Z α1-antitrypsin related emphysema. Am J Respir Cell Mol Biol 2004; 31:133-139.
85. Zhou A, Stein PE, Huntington JA, Sivasothy P, Lomas DA, Carrell RW. How small peptides block and reverse serpin polymerization. J Mol Biol 2004; 342:931-941.
86. Devlin GL, Parfrey H, Tew DJ, Lomas DA, Bottomley SP. Prevention of polymerization of M and Z α1-antitrypsin (a1- AT) with Trimethylamine N-Oxide. Implications for the treatment of α1-AT deficiency. Am J Respir Cell Mol Biol 2001; 24(6):727-732.
87. Burrows JAJ, Willis LK, Perlmutter DH. Chemical chaperones mediate increased secretion of mutant α1-antitrypsin (α1- AT) Z: a potential pharmacologcial strategy for prevention of liver injury and emphysema. Proc Natl Acad Sci USA 2000; 97:1796-1801.
88. Teckman JH. Lack of effect of oral 4-phenylbutyrate on serum alpha-1-antitrypsin in patients with alpha-1-antitrypsin deficiency: a preliminary study. J Pediatr Gastroenterol Nutr 2004; 39(1):34-37.
89. Hidvegi T, Ewing M, Hale P, Dippold C, Beckett C, Kemp C, et al. An autophagy-enhancing drug promotes degradation of mutant alpha1-antitrypsin Z and reduces hepatic fibrosis. Science 2010; 329:229-232.
90. Parfrey H, Mahadeva R, Ravenhill NA, Zhou A, Dafforn TR, Foreman RC, et al. Targeting a surface cavity of α1-antitrypsin to prevent conformational disease. J Biol Chem 2003;278(35):33060-33066.
91. Mallya M, Phillips RL, Saldanha SA, Gooptu B, Leigh Brown SC, Termine DJ, et al. Small molecules block the polymerisation of Z α1-antitrypsin and increase the clearance of intracellular aggregates. J Med Chem 2007; 50(22):5357-5363.
92. Yusa K, Rashid ST, Strick-Marchand H, Varela I, Liu PQ, Paschon DE, et al. Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells. Nature 2011; 478:391-394.
93. Lomas DA, Elliott PR, Chang W-SW, Wardell MR, Carrell RW. Preparation and characterisation of latent α1-antitrypsin. J Biol Chem 1995; 270(10):5282-5288.